ADOCIA a biotechnology company dedicated to protein delivery

  • Contact Us
  • Linkedin
  • RSS
  • LANGUAGES
    • English English
    • Français Français
  • Presentation
    • About Adocia
    • Founders
    • Management
    • Board of Directors
    • Team
    • Scientific Advisory Board
    • Symbol
  • Technology
    • BIOCHAPERONE®
    • Intellectual property
    • Publications
  • Products
    • Pipeline
    • BIOCHAPERONE® LISPRO
    • BIOCHAPERONE® COMBO
    • M1Pram
    • BIOCHAPERONE® GLUCAGON
    • BIOCHAPERONE® Gla GLP-1
    • BioChaperone® Glucagon GLP-1
  • Partnering
    • Licensing Opportunities
    • Contact
  • Financials
    • Home Investors
    • Regulated Information
    • Documentation
    • Shareholders
    • Shareholders meeting
    • Governance
    • Investors Contact
  • Careers
    • Working at Adocia
    • HR Policy
    • Spontaneous application
    • Offers
  • News & Events
    • Press Releases
    • Upcoming Events

BioChaperone®, A versatile platform adapted to a wide range of proteins

Homines enim eruditos et sobrios ut infaustos et inutiles vitant, eo quoque accedente quod et nomenclatores adsueti haec et talia venditare.

To date, Adocia researchers have developed a portfolio of more than 300 BioChaperone® polymers, oligomers and small organic compounds. The main variations among BioChaperone® polymers are size, nature, and number of anionic and hydrophobic grafts. Thanks to this diversity, the BioChaperone® technology has already been applied to three main categories of proteins of different sizes and properties.

 

Insulins

Insulin, a key hormone in the treatment of diabetes, has been combined with BioChaperone® to enhance its pharmacokinetics and pharmacodynamics.

Adocia is currently developing 4 insulin-based products using BioChaperone®:

 

  • BioChaperone® Combo: A combination of prandial and basal insulin based on insulin glargine. BioChaperone technology makes it possible to mix both insulins by solubilizing insulin glargine at Neutral pH.
  • BioChaperone® Lispro. This ultra-rapid insulin, licensed to Eli Lilly since December 2014, is being developed with the goal of optimizing glucose levels during and after meals.
  • BioChaperone® Human Glucagon. Glucagon is another key metabolic hormone which role is schematically opposite to that of insulin. A healthy pancreas secretes both insulin and glucagon to keep blood glucose into a tight physiological range. However, human glucagon is a very unstable molecule and commercially available products may only be reconstituted ex temporane from a lyophilized powder. Using the BioChaperone® technology, Adocia aims to develop a stable aqueous solution of recombinant human glucagon, that may be used in varied settings, including the treatment of severe hypoglycaemia and the use in an artificial pancreas.
  • HinsBet®, a BioChaperone® fast-acting human insulin, accelerates the pharmacokinetic profile of human insulin, aiming to obtain comparable performances to an insulin analog.

 

 

Technology

  • BioChaperone®
  • Intellectual property
  • Publications

BIOCHAPERONE® TECHNOLOGY

  • “Physically glycosylating” proteins
  • A versatile platform

A la Une / Spotlight

  • Adocia-Analyse Department

    France 3 Auvergne Rhône Alpes (French TV) broadcast: Adocia develops faster, more physiologic insulins to improve the lives of people with diabetes. Eve-Marie, T1D, shares her daily life struggles and her hopes for improved life with diabetes.

    In France, more than 3.5 million people live wi...
  • Gérard Soula, Adocia CEO

    BFM TV Broadcast in Adocia laboratory on World Diabetes Day: “Diabetes, an omnipresent disease which now affects one in eleven people worldwide”

    On World Diabetes Day, BFM TV highlighted “the ...

  • Home
  • Terms Of Use
  • Privacy Policy
  • Contact
ADOCIA a biotechnology company dedicated to protein delivery

Copyright ADOCIA © 2018

TOP
Cookies

ADOCIA uses cookies for the effective operation of the Site and to monitor and analyze the traffic on the Site.
The information collected through cookies is solely and strictly for ADOCIA, in compliance with the regulation applicable to the protection of personal data. They are never transmitted to third-parties.